Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023

SELL
$27.71 - $40.93 $430,724 - $636,215
-15,544 Reduced 65.08%
8,339 $245 Million
Q4 2022

Feb 14, 2023

BUY
$29.75 - $39.26 $710,519 - $937,646
23,883 New
23,883 $882 Million

Others Institutions Holding AMLX

About Amylyx Pharmaceuticals, Inc.


  • Ticker AMLX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,533,200
  • Market Cap $290M
  • Description
  • Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...
More about AMLX
Track This Portfolio

Track Artia Global Partners LP Portfolio

Follow Artia Global Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Artia Global Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Artia Global Partners LP with notifications on news.